Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Nutex Health (NUTX) over the last 16 years, with Q3 2025 value amounting to $5.0 million.

  • Nutex Health's Depreciation & Amortization (CF) rose 62.35% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 1224.71%. This contributed to the annual value of $19.0 million for FY2024, which is 784.69% up from last year.
  • Nutex Health's Depreciation & Amortization (CF) amounted to $5.0 million in Q3 2025, which was up 62.35% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, Nutex Health's Depreciation & Amortization (CF) registered a high of $5.3 million during Q4 2024, and its lowest value of $64044.0 during Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $4.2 million (2024), whereas its average is $3.8 million.
  • Data for Nutex Health's Depreciation & Amortization (CF) shows a peak YoY increase of 1533369.89% (in 2021) and a maximum YoY decrease of 6917.39% (in 2021) over the last 5 years.
  • Over the past 5 years, Nutex Health's Depreciation & Amortization (CF) (Quarter) stood at $1.8 million in 2021, then soared by 82.89% to $3.3 million in 2022, then surged by 43.12% to $4.7 million in 2023, then increased by 12.78% to $5.3 million in 2024, then fell by 5.26% to $5.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $5.0 million in Q3 2025, compared to $5.2 million in Q2 2025 and $5.1 million in Q1 2025.